GOG Foundation
Trial Pipeline
Letrozole in Uterine Leiomyosarcoma
NCT05649956
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
NCT05659381
A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer
NCT04831580
A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer
NCT05154487
Studying the Physical Function and Quality of Life Before and After Surgery in Patients With Stage I Cervical Cancer
NCT01649089
CA-IX, p16, Proliferative Markers, and HPV in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells
NCT00892866
Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer
NCT02228681
Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia
NCT01535053
Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery
NCT01101451
Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
NCT00063999
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 30 |
| Phase 3 | 4 |
Therapeutic Areas
What the Pipeline for GOG Foundation Shows
According to the ClinicalTrials.gov registry, GOG Foundation is linked to 37 US clinical trials across every stage of research activity. Of those, 30 studies are currently recruiting — about 81% of the sponsor's indexed portfolio — and 4 are already marked complete, representing roughly 11% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for GOG Foundation reports 4 late-stage studies (Phase 3 and Phase 4 combined) and 30 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for GOG Foundation is Cervical Adenosquamous Carcinoma with 2 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.